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Although malaria and Epstein–Barr (EBV) infection are recognized cofactors in the genesis of endemic Burkitt
lymphoma (BL), their relative contribution is not understood. BL, the most common paediatric cancer in equatorial
Africa, is a high-grade B cell lymphoma characterized by c-myc translocation. EBV is a ubiquitous B lymphotropic virus
that persists in a latent state after primary infection, and in Africa, most children have sero-converted by 3 y of age.
Malaria infection profoundly affects the B cell compartment, inducing polyclonal activation and hyper-gammaglobu-
linemia. We recently identified the cystein-rich inter-domain region 1a (CIDR1a) of the Plasmodium falciparum
membrane protein 1 as a polyclonal B cell activator that preferentially activates the memory compartment, where EBV
is known to persist. Here, we have addressed the mechanisms of interaction between CIDR1a and EBV in the context of
B cells. We show that CIDR1a binds to the EBV-positive B cell line Akata and increases the number of cells switching to
the viral lytic cycle as measured by green fluorescent protein (GFP) expression driven by a lytic promoter. The virus
production in CIDR1a-exposed cultures was directly proportional to the number of GFP-positive Akata cells (lytic EBV)
and to the increased expression of the EBV lytic promoter BZLF1. Furthermore, CIDR1a stimulated the production of
EBV in peripheral blood mononuclear cells derived from healthy donors and children with BL. Our results suggest that
P. falciparum antigens such as CIDR1a can directly induce EBV reactivation during malaria infection that may increase
the risk of BL development for children living in malaria-endemic areas. To our knowledge, this is the first report to
show that a microbial protein can drive a latently infected B cell into EBV replication.
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Introduction
Epstein–Barr virus (EBV) is a human c-herpes virus that
establishes a persistent infection in .90% of the world’s
population. Like other herpes viruses, EBV has two alter-
native lifestyles: latent (non-productive) infection, and lytic
(productive) replication. Following primary infection, EBV
persists within memory B lymphocytes in a latent state for the
life of the host. A low level of reactivation into lytic
replication allows viral shedding into the saliva and trans-
mission of the virus in vivo [1]. The lifelong persistent
infection established by EBV is harmless in almost every host
and rarely causes disease, unless the host–virus equilibrium is
upset. Thus, viral persistence represents a balance between
viral latency, viral replication, and host immune responses.
The lytic phase of viral replication can be triggered in vitro
by a variety of reagents and stimuli, including halogenated
pyrimidine [2], phorbol esters [3], calcium ionophores [4],
transforming growth factor b [5], butyrate [6], and triggering
of the B cell receptor (BCR) with anti-immunoglobulin (anti-
Ig) antibody (Ab) [7]. Less is known about the physiological
stimuli that control activation of the virus productive cycle in
vivo, although replication seems to occur following plasma
cell differentiation [8].
It has been well documented that EBV is causally associated
with various malignancies, including endemic Burkitt lym-
phoma (BL), nasopharyngeal carcinoma, and B cell lympho-
ma, in immunocompromised hosts [9]. Both EBV infection
and intense exposure to Plasmodium falciparum malaria
(holoendemic malaria) are recognized cofactors in the
pathogenesis of BL, which is the most common paediatric
cancer in equatorial Africa, accounting for up to 74% of
childhood malignant disorders [10]. Development of BL, a B
cell malignancy, is heralded by high Ab titers to replicative
antigens indicative of EBV reactivation [11]. Recent reports
indicate that the impact of malaria infection on EBV
persistence is reﬂected by an increased viral replication.
Children living in malaria-endemic areas have an elevated
EBV load [12,13], and acute malaria infection leads to
increased levels of circulating EBV that are cleared following
anti-malaria treatment [14].
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P. falciparum malaria are not well understood. The identi-
ﬁcation of a polyclonal B cell activator and Ig-binding
protein in P. falciparum is of particular relevance in this
context. We demonstrated that the cystein-rich inter-domain
region 1a (CIDR1a) of the P. falciparum erythrocyte mem-
brane protein 1 (PfEMP1) induces proliferation and activa-
tion of B cells, preferentially of the memory subset, where
EBV is known to reside [15,16]. To understand the relative
contribution of malarial antigens on EBV reactivation, we
used the prototype EBV-positive BL cell line Akata as a model
to determine whether CIDR1a could induce reactivation of
the EBV lytic cycle in latently infected B cells. Furthermore,
we analyzed the effect of the CIDR1a on freshly isolated
peripheral blood mononuclear cells (PBMCs) from EBV-
positive healthy donors and from children with BL living in
malaria-endemic areas. The results support the hypothesis
that CIDR1a is one of the molecules involved in EBV
reactivation during the course of malaria infection. Our data
provide new insights into how malaria infection may
contribute to BL development.
Results
P. falciparum–Infected Red Blood Cells and Purified
CIDR1a Bind to EBV-Carrying B Cells
During the blood stage of P. falciparum malaria, infected red
blood cells (iRBCs) express high levels of PfEMP1, reaching
their maximum at the trophozoite stage (28–32 h post-
invasion). The CIDR1a domain of PfEMP1 (clone FCR3S1.2-
var1) has a multi-adhesive phenotype and binds to different
cell surface receptors, such as CD36, PECAM-1 (CD31), and
immunoglobulins (Igs) [17]. CIDR1a also binds to isolated B
cells via an interaction that involves surface Igs [15].
To establish whether iRBCs and the soluble form of
CIDR1a interact with EBV-carrying B cells, we used the
EBV-positive BL cell line Akata as a model. Akata cells stained
with PKH67 (green) were co-incubated with PKH26 (red)-
stained uninfected red blood cells (RBCs), or with enriched
iRBCs at the trophozoite stage (28 h post-invasion, 75%–80%
ﬁnal parasitemia), at a ratio of 1:2, respectively. RBCs did not
bind to Akata (Figure 1A), but co-incubation with iRBCs led
to the formation of conjugates that varied in size but
frequently involved two to ﬁve iRBCs/Akata cell (Figure 1B).
A higher magniﬁcation of the conjugates showed a polar-
ization of the iRBC, where the parasites were found at the
proximity of the membrane’s tight junction between the two
cell types (Figure 1C).
Being that CIDR1a is a domain expressed on iRBCs with
multi-adhesive phenotypes [17], we investigated its ability to
bind Akata cells. A soluble form of CIDR1a was produced as a
glutathione-S-transferase (GST) fusion protein, and the GST
protein alone was used as control. Immunoﬂuorescence
studies with anti-GST ﬂuorescent Abs demonstrated that
CIDR1a, but not the GST control, binds to the membrane of
Akata cells (Figure 1D and 1E). Flow cytometry analysis
showed a peak shift representing an increased mean
ﬂuorescence intensity (MFI) as compared to the MFI values
obtained when Akata cells were incubated with GST control
protein or with the isotype control Ab (Figure 1F). Thus, both
iRBCs and the recombinant CIDR1a domain of PfEMP1 bind
to the EBV-carrying B cell line Akata.
CIDR1a and iRBC Stimulation Lead to Increased EBV Viral
DNA Load in Akata Cells
In contrast to the variety of reagents and signals able to
induce EBV lytic production in vitro [18], the physiological
signals involved in the activation of the virus productive cycle
have not been well characterized yet, although plasma cell
differentiation seems to represent one such trigger [8]. Anti-
Ig treatment, which leads to BCR signalling [19], has served as
a relevant in vitro model of reactivation for inducing virus
replication in some EBV-carrying BL cell lines, including
Akata [7,20].
Because CIDR1a is an Ig-binding protein [17], we analyzed
its functional impact on the reactivation of lytic virus
production and used the well-characterized Akata cell line
model as a read-out system. First, we analyzed whether
stimulation of Akata cells with CIDR1a would affect the
number of viral DNA copies produced. Cells were cultured
with increasing concentrations of CIDR1a, GST (range 0,5–2
lM, corresponding to 25–100 lg/mL), or in medium alone.
After 48 h, we quantiﬁed the EBV viral DNA copy number in
the cultures (cells þ supernatant) by monitoring the EBV
LMP1 gene, which is present as a single copy in the virus
genome. As shown in Figure 2A and 2B, stimulation with
CIDR1a increased the viral DNA load in a dose-dependent
manner. Cells incubated with GST contained numbers of EBV
genomes comparable to that of cells cultured in medium
alone. In two out of four independent experiments, there was
a statistical signiﬁcance in relative increase of EBV load
between the concentrations of 0,5 lM and 2 lM( p ¼ 0,03).
We have recently demonstrated that CIDR1a induces B cell
proliferation and protects B cells from apoptosis [16]. It could
be then argued that the augmented viral load might simply
result from a net increase in the number of cells in the
culture. Cell cycle analysis performed by propidium iodide
staining after 24 and 48 h of incubation did not reveal any
signiﬁcant change in the proportion of dead (,G0/G1) or
cycling cells (S-G2/M) between cultures containing CIDR1a,
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Author Summary
Malaria and Epstein–Barr virus (EBV) infections are recognized
cofactors in the genesis of endemic Burkitt lymphoma, the most
common paediatric cancer in equatorial Africa. EBV is a ubiquitous
virus residing in B lymphocytes that establishes a lifelong
persistence in the host after primary infection. EBV has two lifestyles:
latent infection (non-productive), and lytic replication (productive).
Children living in malaria-endemic areas exhibit an elevated viral
load, and acute malaria infection increases the levels of circulating
EBV. The mechanisms leading to viral reactivation during Plasmo-
dium falciparum malaria infection are not well understood. Cystein-
rich inter-domain region 1a (CIDR1a) is a domain of a large protein
expressed at the surface of P. falciparum–infected red blood cells.
Based on previous findings showing that CIDR1a activates and
expands the B cells compartment where EBV persists, we assessed
the impact of CIDR1a on viral reactivation. Here, we identify CIDR1a
as the first microbial protein able to drive a latently EBV-infected B
cell (no virus production) into lytic replication (virus production). Our
results suggest that P. falciparum–derived proteins can lead to a
direct reactivation of EBV during acute malaria infection, increasing
the risk of Burkitt lymphoma development for children living in
malaria-endemic areas.GST, or medium alone (unpublished data). Moreover, experi-
ments carried out in the presence of z-VAD, a pan-speciﬁc
caspase inhibitor that blocks apoptosis, did not signiﬁcantly
affect the extent of EBV DNA increase in cultures containing
GST or CIDR1a (Figure 2B), ruling out the involvement of
apoptosis. In conclusion, stimulation of the EBV-carrying B
cell line Akata with CIDR1a leads to an increased number of
viral genomes that is not dependent on apoptosis or
increased proliferation.
The interaction between iRBCs and B cells is partially
mediated by CIDR1a [15] that is expressed at the iRBC
surface along with a variety of other antigens [21]. Therefore,
it became of interest to see whether the interaction of Akata
cells with iRBCs would lead to viral reactivation. Intact iRBCs
could not be used for this purpose, as detection of viral
production requires 48 h of co-incubation with Akata, and
during this time the iRBCs burst, leading to toxicity and cell
death. The erythrocytic parasite cycle from invasion to
merozoite release takes 48 h and the puriﬁcation of
synchronized iRBCs requires a high cellular content of the
paramagnetic pigment hemozoin that is reached 28 h post-
invasion; i.e., the rupture would occur in the middle of the
test. To overcome the iRBC burst and the related cytotoxicity,
we used crude extracts from RBCs and iRBCs obtained 28 h
post–parasite invasion. Incubation with iRBC extracts re-
sulted in increased viral production as compared to exposure
to RBC extracts (Figure 2C). The above results suggest that
iRBC-derived molecules can induce viral production,
although the role played by CIDR1a in this context is difﬁcult
to assess.
The Increased Viral Copy Number Induced by CIDR1a
Reflects Induction of the Lytic Cycle
To investigate whether the increased number of EBV
genomes resulted from lytic cycle reactivation, we used an
Akata cell line–based system in which induction of the lytic
cycle is accompanied by increased expression of green
ﬂuorescent protein (GFP). Upon BCR cross-linking with
anti-Ig, 20%–50% of cells typically enter the replicative
cycle. Cells that support lytic replication up-regulate GFP (10-
to 100-fold), whereas cells that remain in latency express little
GFP. The kinetics of GFP expression follows that of early lytic
genes. The GFP expression persists throughout the lytic cycle
[22], and is therefore used as a quick and simple read-out for
viral replication.
Akata-GFP cells were incubated with increasing concen-
trations of CIDR1a and GST for 48 h, at which time the
e x t e n to fc e l l se x p r e s s i n gG F Pw a sm e a s u r e db yﬂ o w
cytometry. Cells induced to lytic replication, either with
CIDR1a or anti-Ig stimulation, and therefore expressing high
levels of GFP, had a higher granularity (side scatter) and a
minor increase in size (forward scatter) as compared to the
GFP-negative population. These cellular changes reﬂect an
activated status. Analysis of the data, gating on the region
containing highly granular cells, showed that the increase in
GFP-positive cells was 1,4 to 2,4 times higher among the
CIDR1a-stimulated cells than in the GST control cultures.
Figure 1. P. falciparum iRBCs and Soluble CIDR1a Bind to the EBV-Positive B Cell Line Akata
(A–C) Akata cells stained with PKH67 (green) were co-incubated with RBCs stained with PK26 (red) (A) or with purified iRBCs (B, C) at a ratio of 1:2
(Akata:iRBC). Binding was evaluated by light microscopy (left panel) and immunofluorescence microscopy (right panel). (C) Magnification of the binding
between iRBCs and Akatas. Localization of the parasite in the iRBC (indicated by white arrows) was revealed using phase contrast microscopy (left panel).
(D–F) Akata cells were incubated with soluble GST (1 lM) (D) or CIDR1a (1 lM) (E) for 1 h at RT and stained with anti-GST Ab and anti-mouse Alexa-488-
conjugated Ab. The binding was evaluated by light microscopy (left panel, [D, E]), immunofluorescence microscopy (right panel, [D, E]), and fluorescent-
activated cell sorting (FACS) analysis (F).
doi:10.1371/journal.ppat.0030080.g001
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cultured with 1 lM CIDR1a versus 5%–9% for cells cultured
with GST (Figure 3A).
The increased proportion of cells in lytic cycle (GFP-
positive) induced by CIDR1a treatment correlated with a rise
in the number of viral genomes as measured by quantitative
PCR. The rise in the proportion of GFP-positive cells after
CIDR1a stimulation was directly proportional to the increase
of EBV load (R
2 ¼ 0.90; p , 0,001) (Figure 3B).
Activation of lytic production by CIDR1a was further
conﬁrmed by analysis of the BZLF1 protein (also known as Z,
Zebra, Zta, EB1) expression. BZLF1, an immediate early
protein which acts as a transcriptional activator and disrupts
EBV latency, is essential for full expression of lytic genes and
viral DNA replication [23]. The kinetics of BZLF1 expression
vary according to the infected cell type and the replication-
inducing agent used. As early as 6 h after induction by surface
Ig cross-linking, Akata cells start expressing BZLF1 and
continue doing so throughout the lytic cycle [22]. Stimulation
with CIDR1a led to an increased expression of BZLF1 in a
CIDR1a dose-dependent manner as revealed by Western blot
analysis 48 h after stimulation (Figure 3C). These results
support the hypothesis that CIDR1a activation induces viral
reactivation in EBV-carrying B cells. Taken together, the data
indicate that the increased viral load induced by CIDR1a in
Akata cells results from a switch in EBV from latency to the
replicative lytic cycle.
CIDR1a Stimulation Increases the Viral Copy Number in B
Cells Derived from EBV-Positive Donors
B cells derived from the mucosal lymphoid tissue of the
Waldeyer ring (tonsils) have a ten times higher frequency of
Figure 2. CIDR1a and iRBC Stimulation Lead to Increased Viral Load in Akata Cells
(A) Akata cells were cultured in medium alone (referred to as Ag concentration 0) with GST (white circles) or with CIDR1a (black circles) at protein
concentrations ranging from 0,5 to 2,5 lM in the presence or absence of zVAD. After 48 h of incubation, the viral genome copy number was determined
by real-time PCR. Results from a representative experiment (out of four independent experiments) are expressed as numbers of EBV genome copies per
lg of total DNA.
(B) Akata cells were cultured with GST or CIDR1a (0–2,5 lM), and with anti-Ig (10 lg/mL). After 48 h of incubation, the viral genome copy number was
determined by real-time PCR. Results are expressed as percentage of relative increase in EBV copy number in cultures stimulated with CIDR1a versus
cultures stimulated with GST, and represent the mean of four independent experiments 6 standard deviation. *, p2vs0,5 lM ¼ 0,03.
(C) Akata cells were cultured with increasing concentrations of crude extracts from iRBCs and RBCs. After 48 h of incubation, the viral genome copy
number was determined by real-time PCR. Results from one representative experiment (out of three performed) are expressed as percentage of relative
increase in EBV copy numbers in cultures stimulated with iRBCs versus cultures stimulated with RBC extracts.
doi:10.1371/journal.ppat.0030080.g002
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Malaria and EBV Reactivationvirus-infected cells as compared to peripheral blood B cells
[24]. To investigate the possible physiological impact that
malaria infection has on EBV persistence, we analyzed the
effect of CIDR1a on PBMCs and B cells derived from healthy
EBV-positive donors with regard to quantitative changes in
EBV DNA. PBMCs were co-incubated with CIDR1a, and after
48 h, the EBV genome copy number was quantiﬁed by real-
time PCR and compared to the one in the GST/medium
control cultures. This analysis was extended to PBMCs
derived from children with BL living in malaria-endemic
area.
Stimulation of tonsil B cells with CIDR1a increased by 3-
fold the number of EBV genomes as compared to the control
antigen (p ¼ 0,04) (Figure 4A). In PBMCs, where the B cell
number and the frequency of EBV-positive cells is lower,
stimulation with CIDR1a led to a 1,4- and 2,5-fold increase in
EBV genomes (Figure 4B). This increase was statistically
signiﬁcant (pDonor1 ¼ 0,04; pDonor2 ¼ 0,001). The two healthy
donors used for this study have an elevated number of EBV-
carrying B cells as reﬂected by a high frequency of
spontaneous outgrowth of EBV-positive B cells when their
PBMCs are cultured in vitro. The absolute levels of EBV
genomes in PBMCs are lower than the ones in tonsil B cells, a
fact that may be the result of a lower frequency of EBV-
carrying B cells in PBMCs.
Although EBV infection is usually harmless, EBV is linked
Figure 4. Stimulation of Tonsil B Cells and PBMCs from EBV-Positive Donors and BL Patients with CIDR1a Increases the EBV Load
(A) Tonsil B cells were cultured in medium alone (white bar), with GST (1 lM) (light grey bar), and with CIDR1a (1 lM) (dark grey bar). After 48 h of
incubation, the viral genome copy number in the cultures was determined by real-time PCR. *, p ¼ 0,04.
(B) PBMCs from two EBV-positive healthy donors were cultured with GST (1 lM) (white bars) and with CIDR1a (1 lM) (dashed bars). After 48 h of
incubation, the viral genome copy number in the cultures was determined by real-time PCR. Data are expressed as EBV copies/mL. Vertical bars depict
median values, with 25th and 75th percentile values represented by the bottom and top edges of the bar. Each bar shows the EBV load from one
patient measured in multiple replicates and in three independent experiments. *, pDonor1 ¼ 0,04; *, pDonor2 ¼ 0,001.
(C) PBMCs from children with BL were cultured with medium or GST (1 lM), our internal controls (C), and with CIDR1a (1 lM). After 48 h of incubation,
the viral genome copy number in the cultures was determined by real-time PCR. Data are expressed as EBV copies/mL. Vertical bars depict median
values, with 25th and 75th percentile values represented by the bottom and top edges of the bar. Each bar shows the EBV load measured in multiple
replicates. *, pBL2 ¼ 0,01; *, pBL3 ¼ 0,01; *, pBL6 ¼ 0,0003; *, pBL7 ¼ 0,03.
doi:10.1371/journal.ppat.0030080.g004
Figure 3. Induction of EBV Lytic Cycle in Akata-GFP Cells upon Stimulation with CIDR1a
(A) Akata-GFP cells were cultured in medium alone, with GST (4 lM), with CIDR1a (0,12–4 lM), or with anti-Ig (10 lg/mL). After 48 h of incubation, a
FACS analysis was performed. Cell populations were divided into cells with low granularity (LG) and cells with high granularity (HG) on the basis of side
scatter (SSC). The proportion of cells in lytic cycle (GFP-positive) was then quantified in the HG subpopulation. The figure shows one representative
experiment. FSC, forward scatter.
(B) Akata-GFP cells were cultured with GST (2 lM), with CIDR1a (0–2 lM), and with anti-Ig (10 lg/mL). After 48 h of incubation, the proportion of GFP-
positive cells was quantified by FACS analysis (circles), and the EBV DNA load was assessed by real-time PCR (diamonds). The left y-axis denotes the
proportion of Akata-GFP–positive cells in lytic cycle, the right y-axis denotes the number of EBV genomes. Controls included GST-stimulated (empty
diamonds/circles) and anti-Ig–stimulated cells (filled diamonds/circles). Data show the mean of three independent experiments.
(C) Akata cells up-regulate BZLF1 upon stimulation with CIDR1a. Akata-GFP cells were cultured with GST (1,5 lM) or with CIDR1a (0,25–1,5 lM). After 48
h of incubation, the expression of BZLF1 was analyzed by Western blot. Increased BZLF1 expression in CIDR1a stimulated samples was confirmed by
relative quantitative analysis with Quantity One software (Bio-Rad).
doi:10.1371/journal.ppat.0030080.g003
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Malaria and EBV Reactivationto several human cancers and it is recognized as a cofactor in
the development of the endemic form of BL, in which
virtually all tumour cells are EBV-positive. We have pre-
viously shown that the overall EBV DNA load is elevated in
serum from children with BL [14]; therefore, it can be
assumed that PBMCs from BL patients have a high frequency
of EBV-positive B cells. Thus, we tested the effect of CIDR1a
on PBMCs derived from seven Ugandan patients with BL. In
four out of seven patients, stimulation with CIDR1a (2 lM)
for 48 h resulted in an increased median viral load as
compared to that of control cultures. The difference was
statistically signiﬁcant (p   0,03) (Figure 4C). Although the
overall median value was comparable in CIDR1a- and GST-
treated PBMCs in two of the three other patients, there were
few replicate wells with higher EBV load compared to
respective GST control (for both patients). Consequently,
we conclude that CIDR1a stimulation increases the viral load
in EBV-carrying B cells derived from EBV-positive healthy
donors and in patients with BL.
Discussion
Despite the well-established link between malaria and EBV
infection with BL, little is known about the interaction
between the two pathogens and the mechanisms responsible
for the elevated EBV load observed in children living in
malaria-endemic areas [12,25]. In this report, we identify, to
our knowledge for the ﬁrst time, a microbial protein from P.
falciparum, that can drive a latently infected B cell into viral
replication. Previous studies by Minoura-Etoh et al. demon-
strated that monochloramine (NH2Cl), a Helicobacter pylori–
associated oxidant, induces viral production in epithelial cells
[26].
Following primary infection, EBV is kept latent within
memory B cells. In vivo, terminal differentiation of B cells
into plasma cells triggers the switch from latency into the
lytic replicative cycle [8]. Signalling of BCR is initiated upon
binding of the antigen to the membrane-bound Igs, and this
activation contributes to cell differentiation and Ab produc-
tion. The EBV reactivation in Akata cells that results from
BCR cross-linking with anti-Ig may reﬂect physiological
mechanisms that operate as latently infected memory B cells
proceed through the germinal center reaction and/or under-
go plasma cell differentiation. Given the fact that both
CIDR1a and iRBCs bind non-immune Igs [15,27], it could be
assumed that the induction of virus replication in Akata cells
mediated by CIDR1a and by iRBC extracts may involve
similar signalling pathways. We cannot ascertain that CIDR1a
is the only molecule responsible for the viral production
induced by iRBC crude extracts, because in addition to
CIDR1a, iRBCs express other malarial antigens that could
play a role in viral reactivation.
Children living in malaria-endemic areas have an elevated
EBV load that is cleared after anti-malaria therapy [14] and is
directly related to the level of endemicity [12]. The rise in
viral load may partly be a consequence of the interaction
between malarial antigens able to bind Igs and latently
infected B lymphocytes. The interaction between B cells and
iRBCs is of particular relevance; we have reported that non-
immune B cells bind iRBCs, and that this interaction is
partially mediated by CIDR1a on the iRBC membrane and Igs
on the B cell surface [15]. Here, we show that the iRBCs and
the malaria parasite protein CIDR1a bind to the EBV-positive
B cell line Akata. Most likely, the Ig-binding capacity of
CIDR1a [15] and potentially other P. falciparum antigens
present on iRBCs could lead to viral replication in a manner
similar to the way anti-Ig induces viral production in Akata
cells. This assumption is based on the fact that CIDR1a
induces B cell activation and Ab production, and preferen-
tially activates memory B cells, where the virus persists
[15,16]. The role of malaria infection in enhancing viral
replication is further supported by our previous observation
that acute malaria patients have high levels of Abs against the
early viral lytic protein BZLF1 [14].
As a corollary of the in vitro experiments, it was important
to analyze the impact of CIDR1a on PBMCs and tonsil B cells
derived from healthy EBV-positive donors, and from patients
with BL. As judged by quantiﬁcation of EBV DNA, CIDR1a
increased viral production. In healthy donors, the effect was
more pronounced in tonsil B cells than in PBMCs. We believe
that this observation reﬂects inherent differences in the
frequency of memory B cells, as EBV-positive B cells are more
frequent among tonsil B cells than in PBMC preparations
[24].
EBV reactivation is suspected to play a role in BL
lymphomagenesis and is indicated by the presence of high
Ab titers to viral lytic components, which characteristically
herald the onset of BL [11]. It has been previously suggested
that BL may rise as a consequence of the combination of
multiple mechanisms that involve chronic stimulation of the
B cell compartment, increased viral production, and sup-
pressed EBV-speciﬁc responses (reviewed by [28,29]). Our
previous and present studies indicate that malaria has
inherent effects on EBV–host balance that contribute to the
abnormal viral load present in children from malaria-
endemic areas and likely result in an increased risk for BL.
In addition, the polyclonal B cell–activating capacity of
malaria may increase the proliferation of EBV-positive cells
[15]. The present data demonstrate that iRBCs and antigens
related to the infectious cycle of malaria (such as CIDR1a) can
trigger lytic production in EBV-carrying B cells. In vivo, the
viral reactivation mediated by CIDR1a and other malaria-
derived antigens might take place in the spleen, where the
probability of trapped iRBCs to encounter EBV-carrying B
cells is high, as over 40% of the splenocytes are B cells.
Notably, splenomegaly is often observed in children living in
highly endemic areas where BL occurs [30].
In conclusion, interactions between P. falciparum malaria
and EBV could play a direct role in promoting the emergence
of BL.
Materials and Methods
Cell lines. Akata, a human BL-derived cell line carrying EBV, was
maintained in RPMI 1640 (GIBCO-BRL, http://www.invitrogen.com)
supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and
2 mM glutamine, hereafter referred to as complete medium. The
Akata GFP was previously generated by infecting the EBV-negative
variant of Akata line with a recombinant EBV virus, carrying a
cassette that encodes for both neomycin resistance gene under
control of a thymidine kinase promoter and a modiﬁed GFP gene
under control of the cytomegalovirus immediate early promoter [31].
With the recombinant EBV, the neomycin resistance gene and the
modiﬁed GFP gene are inserted into the open reading frame of the
non-essential EBV thymidine kinase gene (BXLF1) [31]. Akata cells
were maintained in complete medium, and Akata-GFP cells in
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Sigma-Aldrich, http://www.sigmaaldrich.com).
Patients. BL patients were recruited from the Ugandan Cancer
Institute, Mulago Hill, Kampala, Uganda. Blood was collected from
children with BL (range 4–7 y; mean age 5 y). BL was diagnosed on the
basis of clinical symptoms, presence of a tumour mass, and
histological analysis. The study protocol was approved by the higher
degrees of the university, the research committee and ethical
committee of Makerere University Faculty of Medicine, the Uganda
National Council of Science and Technology, and the Karolinska
Institutet Research Ethical Committee. Written, informed consent
was obtained from guardians of study participants.
Cell isolation. Blood samples collected from two EBV-positive
healthy volunteers (15–20 mL) and from BL patients (2–5 mL) before
chemotherapy were processed the same day. PBMCs were isolated by
centrifugation over Ficoll Plaque Plus (Amersham, http://www.
amersham.com), washed in PBS, and resuspended in complete
medium. Tonsils were obtained from patients undergoing routine
tonsillectomy at Karolinska University Hospital in Stockholm,
Sweden. Lymphocyte cell suspensions were prepared by mincing
the tonsils and suspending the cells in complete medium. Isolated
mononuclear cells were depleted of T cells by two rounds of rosette
formation with ethyl isothiouronium bromide–treated sheep RBCs on
ice. Rosettes were removed by centrifugation over lymphoprep
(Nycomed Pharma, http://www.nycomed.com) [32]. The tonsil B cell
purity was .95% as revealed by cytoﬂuorimetric (FACS) analysis after
staining with the pan–T cell Ab CD3 and the monocyte marker CD14.
Parasites. The highly rosetting and auto-agglutinating P. falciparum
parasite clone FCR3S1.2 was obtained through cloning by micro-
manipulation of the mother clone FCR3 [33] and cultured according
to standard methods. Parasites were maintained and expanded in
RBCs (O Rh
þ) at 5% haematocrit. iRBCs were cultured in RPMI 1640
medium supplemented with 10% Bþ human serum, 0,6% HEPES
(GIBCO-BRL), 25 lg/mL gentamycin (GIBCO-BRL), 0,25% sodium
bicarbonate (GIBCO-BRL), and 2 mM L-glutamine (GIBCO-BRL).
Trophozoites were enriched by magnetic-assisted cell sorting, using a
Vario-MACS (Miltenyi Biotec, http://www.miltenyibiotec.com). Syn-
chronous P. falciparum parasite cultures, grown 24–28 h post-invasion,
were washed twice in RPMI 1640 and resuspended in 5–10 mL of
phosphate-buffered saline (PBS) with 2% bovine serum albumin
(BSA). Rosettes were disrupted mechanically by repeated passage
through a 0,6-mm-thick injection needle. The material was slowly
added to a MACS separation column mounted in the magnet and
rinsed with 50 mL of 2% BSA in PBS. The iRBCs were eluted in 50 mL
of 2% BSA in PBS after removing the column from the magnet, spun
down at 500g, and resuspended in 1 mL of RPMI 1640. Following
enrichment, the parasitemia was evaluated by ﬂuorescence micro-
scopy after addition of one drop of acridine orange (10 lg/mL).
Parasite extracts. Parasite extracts were prepared as previously
described [34]. Brieﬂy, parasites at trophozoite stage (iRBCs, 28 h
post-invasion) or RBCs were washed, resuspended in PBS, and
sonicated (25w) on ice at short intervals for 2 min. The extracts were
then centrifuged at 500g for 10 min at 4 8C and ﬁlter-sterilized. After
determination of protein concentration by Bradford Assay (Bio-Rad,
http://www.bio-rad.com), the extracts were diluted with PBS.
Recombinant CIDR1a. The sequence of the CIDR1a domain of the
PfEMP1 from clone FCR3S1.2-var1 was optimized for codon
adaptation in Escherichia coli, re-synthesized chemically (GeneArt,
http://www.geneart.com), cloned into the pGEX4T-1 vector (Amer-
sham Pharmacia, http://www.gelifesciences.com), and expressed in E.
coli BL21 CodonPlus-RIL (Stratagene, http://www.stratagene.com) as
fusion protein with the GST. Non-recombinant pGEX4T-1 was used
to produce GST as control protein. Protein puriﬁcation was carried
out according to an optimized protocol [35], and the recombinant
protein was puriﬁed on glutathione-sepharose column GSTrap FF
(Amersham Pharmacia) according to the manufacturer’s instructions.
Throughout the paper, we refer to the recombinant CIDR1a-GST
fusion protein as CIDR1a, while GST is referred to as control protein.
Binding assays. Akata iRBCs: Akata cells and enriched iRBCs
(trophozoite stage) were stained with PKH67 (green) and PKH26 (red)
(Sigma-Aldrich), respectively, according to manufacturer’s instruc-
tions. The binding was evaluated by ﬂuorescence microscopy after co-
incubation in PBS at room temperature (RT) for 1 h at a 1:2 ratio
(Akata:iRBC).
Akata CIDR1a: Cells incubated for 1 h at RT in PBS containing GST
or CIDR1a (1 lM) were washed twice in PBS and incubated for 30 min
at RT with anti-GST Abs (Sigma-Aldrich) diluted 1:500 in PBS. After
two washes with PBS, anti-mouse IgG Alexa-488-conjugated Ab
(Molecular Probes, http://probes.invitrogen.com) diluted 1:100 in PBS
was added for 30 min at 4 8C. Cell binding was analyzed by
ﬂuorescence microscopy, and the ﬂuorescence intensity was meas-
ured with a FACSCalibur ﬂow cytometer and analyzed with Cell
Quest Pro software (Becton Dickinson, http://www.bd.com).
Stimulation assays. Twenty-four hours before experiments, Akata
and Akata-GFP cells were suspended at a concentration of 10
6/mL in
complete medium and complete medium containing G418 (500 lg/
mL), respectively. Fresh PBMCs were washed with PBS and
resuspended in complete medium at a concentration of 10
5 cells
per ml. The cells were then seeded in 96-well plates and cultured in
medium alone or with increasing concentrations of CIDR1a, GST
(range 0–4 lM, corresponding to 0–200 lg/mL), or with anti-Ig (10 lg/
mL) (Jackson ImmunoResearch, http://www.jacksonimmuno.com).
After 48 h, cells were harvested for analysis. All tests were set up in
multiple replicates.
EBV DNA detection by real-time PCR. DNA was extracted from
cells and supernatants using the QIAamp Blood kit (Qiagen, http://
www.qiagen.com)accordingto manufacturer’s instructionsand eluted
in 50 lL of DEPC-treated water (Ambion, http://www.ambion.com).
Purity and DNA concentration were evaluated using a NanoDrop ND-
1000 spectrophotometer (http://www.nanodrop.com). The PCR pri-
mers and probe used for the quantiﬁcation of EBV genomes were
selected from the LMP-1 gene as previously described [13,14]. The
primers used were the EBV-LMP1 forward primer 59-AAGGTCAAA-
GAACAAGGCCAAG-39 and the EBV-LMP1 reverse primer 59-
GCATCGGAGTCGG-39. The ﬂuorogenic probe (PE Applied Biosys-
tems, http://www.appliedbiosystems.com) was synthesized using a FAM
reporter molecule attached to the 59 end and a TAMRA quench-
er linked to the 39 end (59-AGGAGCGTGTCCCCGTGGAGG-39). A
standard curve was prepared using serial dilutions of DNA derived
from the EBV-positive BL line Namalwa that contains two copies of
EBV genome per cell. Detection was performed using an ABI Prism
7700 Sequence detection System (PE Applied Biosystems). Brieﬂy,
cycling parameters were 50 8C for 2 min, 95 8C for 10 min, 45 cycles 95
8C for 15 s, and 60 8C for 1 min. The EBV DNA copy number was
calculated as mean of triplicates.
Cell cycle analysis. Cells were washed twice in ice-cold PBS and
resuspended in 100 lL of PBS containing 50 lg propidium iodide/mL
and 0.1% (v/v) triton X-100. After incubation at 4 8C for 8 h, cell DNA
analysis was performed by ﬂow cytometry (FACSCalibur, Becton
Dickinson) using Cell Quest Pro software (Becton Dickinson). p-
Values   0,05 were regarded as statistically signiﬁcant.
Western blot analysis. Expression of BZLF1, the early lytic antigen,
was assessed using a speciﬁc mouse Ab (DAKO, http://www.dako.com).
Total extracts from 10
6 cells were separated in 10% SDS poly-
acrylamide gels, blotted onto nitrocellulose ﬁlters probed with 1:500
dilution of the DAKO monoclonal Ab for 1 h at RT, and then reacted
with horseradish-peroxidase–labelled anti-mouse Abs (Amersham).
Immunocomplexes were visualized by enhanced chemiluminescence
according to the manufacturer’s instructions (Amersham). To control
for equal loading, the total protein concentration of each sample was
checked using Bradford assay.
Statistical analysis. Computations were performed with the Prism
4 package (GraphPad Software, http://www.graphpad.com). For para-
metric data, differences between groups were analyzed with Student
t-test; for nonparametric data, differences between groups were
analyzed with the Wilcoxon rank sum test. Results are expressed as
mean 6 SEM, and unless otherwise stated, considered statistically
signiﬁcant at p , 0,05.
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